| アブストラクト | BACKGROUND: Immune-related adverse events(irAEs) are common among cancer patients receiving dual immune checkpoint inhibitors (ICI). Cardiac adverse events rank among the most severe categories of such reactions. This study aims to investigate the characteristics and influencing factors of cardiac adverse events associated with dual ICIs. METHODS: We collected data on cardiac adverse events associated to dual ICIs from the U.S. Food and Drug Administration Adverse Event Reporting System database (FAERS), covering the period from the first quarter of 2015 to the fourth quarter of 2024. A disproportionality analysis was performed to assess the association between different dual ICIs and cardiac adverse events, and a comprehensive study was conducted to identify potential influencing factors. RESULTS: Cardiac adverse events accounted for 7.5% of all ICI adverse event reports in the FAERS database. Nivolumab plus ipilimumab was associated with the highest number of significant PT (Preferred Term) signals, while durvalumab plus tremelimumab had the highest percentage of life-threatening outcomes. The median onset time for cardiac adverse events following dual ICIs therapy was 32 days (IQR 15-77). Myositis and myasthenia gravis were the most commonly co-reported extracardiac conditions in myocarditis cases, whereas complete atrioventricular block and cardiogenic shock were the most frequently reported intracardiac complications. Older patients, males, and those with kidney cancer were at higher risk of developing cardiac adverse events. CONCLUSIONS: This study identified distinct associations between different dual ICIs treatment strategies and various cardiac adverse events. We further identified potential risk factors and co-reported symptoms of cardiotoxicity, which may aid in the early diagnosis and monitoring of ICI-associated cardiac adverse events. |
|---|
| ジャーナル名 | European heart journal. Cardiovascular pharmacotherapy |
|---|
| Pubmed追加日 | 2026/1/22 |
|---|
| 投稿者 | Xia, Huang; Shi, Lei; Luo, Shuimei; Sun, Zequn; Quan, Mengru; Xiao, Huazhen; Chen, Yu; Lin, Jing |
|---|
| 組織名 | Phase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical;University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China.;NHC Key Laboratory of Cancer Metabolism (Fujian Cancer Hospital), Fuzhou 350000,;Fujian Province, China.;Department of Medical Oncology, Clinical Oncology School of Fujian Medical;Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical;Department of Chemistry, Fuzhou University, Fuzhou 350108, People's Republic of;China.;Department of Cardiology, Shengli Clinical Medical College of Fujian Medical;University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial;Hospital, Fuzhou, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41565210/ |
|---|
